Month: September 2020

BALA CYNWYD, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) — Leading private markets asset management firm Hamilton Lane (NASDAQ: HLNE) today announced the appointment of longtime Managing Director Paul Yett to the role of Director of ESG & Sustainability. Hamilton Lane has demonstrated a long-standing commitment to ESG, sustainability and responsible investing, and Yett will focus on expanding and formally spearheading the firm’s ESG integration strategy going forward.His responsibilities will include managing ESG integration throughout the investment processes across the Fund, Direct Investment, Secondary, Real Asset and Direct Credit teams; driving ESG policy development and advising deal teams during due diligence; supporting clients, government entities and other stakeholders in regards to ESG and sustainability matters; and overseeing...

 Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”)Preliminary Results for the year ended 30 June 2020Record level of pre R&D operating profit supported by robust sales and operational efficiencyStrong cash position with Grass MATA MPL Phase III programme and initial Phase I peanut trial fully fundedExclusive licencing agreement signed for further virus like particle(VLP) candidates             23 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, today announces its preliminary results for the year ended 30 June 2020.Financial Highlights7% revenue growth at constant rate* and 6% at reported rate to £78.2m (2019: £73.7m)25% increase in pre-R&D operating profit to £14.2m (2019: £11.3m) as a result of sales growth...

AMRYT PHARMA PLC(“Amryt” or the “Company”)AMRYT SUPPORTS GLOBAL FH AWARENESS DAY – SEPTEMBER 24, 2020DUBLIN, Ireland, and Boston MA, September 23 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announces its support today for Global FH Awareness Day 2020 which will take place on Thursday, September 24, 2020.Dr Joe Wiley, CEO of Amryt Pharma, commented: “All of the Amryt team are pleased to support the great work of the FH Foundation in the US and FH Europe as they seek to raise awareness of FH and HoFH amongst patients, clinicians and the wider community. For our part, we are collaborating with all stakeholders to continue to deliver therapies to patients...

STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commencement of the phase 3 clinical program of SEL-212 for chronic refractory gout, with the randomization of the first patient in the study.“We are pleased to have commenced the phase 3 DISSOLVE program evaluating SEL-212 in two phase 3 double-blind, placebo-controlled studies,” said Carsten Brunn, Ph.D., President and CEO of Selecta. “SEL-212 serves as an important validation of Selecta’s ImmTORTM platform, and we are proud to have advanced it into late-stage clinical studies. In partnership with Sobi, we look forward to enrolling patients in the studies and continuing to evaluate SEL-212 as a new, once-monthly treatment option for patients...

– Band n79 Filter for New Small Cell Product Aimed at 5G Network Operators –– Akoustis Expects Production Ramp in Early CY21 –Charlotte, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has received a design win and pre-production order for band n79 XBAW™ filters from a new 5G small cell network infrastructure customer. This is the second customer in 5G small cell infrastructure where Akoustis now has more than five active engagements.The new customer has completed sampling of the Akoustis band n79 filter and plans to use the current order to complete qualification and test its new 5G network infrastructure...

BUFFALO, N.Y., Sept. 23, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients.TCRT-ESO-A2 is being developed by Axis Therapeutics Limited, a joint venture between Athenex and Xiangxue Life Sciences Limited (“XLifeSc”), a subsidiary of Xiangxue Pharmaceutical Co., Ltd. (Shenzhen Exchange: 300147). TCRT-ESO-A2 is similar to TAEST16001, an autologous cell-based therapy being developed simultaneously...

IRVINE, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX) a global provider of Software as a Service (SaaS), engineering services and hardware for Edge Computing, the Internet of Things (IoT) and Remote Environment Management (REM), today announced its new Open-Q™ 865XR System on Module (SOM) solution for IoT applications. With the Open-Q 865XR SOM, Lantronix is leading the way to next-gen intelligent Augmented Reality/Virtual Reality (AR/VR) applications in AI machine learning, medical, gaming, logistics and retail sectors.“Our new Open-Q 865XR SOM gives product developers AR/VR capability at the edge, powerful general processing capability and professional-quality imaging needed to kickstart IoT application development,” said Jonathan Shipman, VP of Strategy at Lantronix Inc.Lantronix’s Open-Q 865XR SOM is...

LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical stage, fully-integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces their supply agreement with Thermo Fisher Scientific Inc. (“Thermo Fisher”).This agreement secures dedicated production capacity and resources for Freeline from 2021 to 2027, inclusive. This will provide capacity for the planned Phase 2b/3 pivotal clinical trial and potential commercialisation of Freeline’s haemophilia B program, FLT180a, using the Company’s proprietary manufacturing platform and processes.Freeline has established the manufacturing process for FLT180a at Thermo Fisher’s Cambridge...

CAMBRIDGE, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 8,333,334 of its ordinary shares at a price to the public of $12.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 of its ordinary shares on the same terms and conditions. The...

BEIJING, Sept. 23, 2020 (GLOBE NEWSWIRE) — 36Kr Holdings Inc. (“36Kr” or the “Company”) (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced a business collaboration agreement (the “Agreement”) with Youku Tudou Inc. (“Youku”), a leading online long-form video platform in China and a key distribution platform for digital media and entertainment content under Alibaba Group (“Alibaba”). The collaboration with Youku will help further expand the Company’s content ecosystem and accelerate the commercialization of its content productions.Pursuant to the Agreement, 36Kr and Youku will jointly develop pan-commercial themed video programs to enrich the Company’s content ecosystem and attract more renowned content creators in the commercial vertical. The integration...